Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Yanan Kuang, Ph.D.

Co-Author

This page shows the publications co-authored by Yanan Kuang and Cloud Paweletz.
Connection Strength

1.766
  1. Monitoring of Response and Resistance in Plasma of EGFR-Mutant Lung Cancer Using Droplet Digital PCR. Methods Mol Biol. 2018; 1768:193-207.
    View in: PubMed
    Score: 0.742
  2. Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancer. NPJ Breast Cancer. 2018; 4:22.
    View in: PubMed
    Score: 0.193
  3. Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients. Clin Cancer Res. 2016 Feb 15; 22(4):915-22.
    View in: PubMed
    Score: 0.159
  4. Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance. Mol Cancer Ther. 2022 02; 21(2):322-335.
    View in: PubMed
    Score: 0.061
  5. Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR-mutant lung cancer. Sci Transl Med. 2021 Sep; 13(609):eabb3738.
    View in: PubMed
    Score: 0.060
  6. Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia. Cancer Cell. 2020 12 14; 38(6):872-890.e6.
    View in: PubMed
    Score: 0.057
  7. Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer. Nat Commun. 2020 05 11; 11(1):2350.
    View in: PubMed
    Score: 0.055
  8. Circulating Donor-derived Cell-free DNA as a Biomarker in Vascularized Composite Allotransplantation? Transplantation. 2020 03; 104(3):e79-e80.
    View in: PubMed
    Score: 0.054
  9. Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors. Clin Cancer Res. 2019 12 15; 25(24):7287-7293.
    View in: PubMed
    Score: 0.052
  10. Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses. Nat Med. 2018 08; 24(8):1143-1150.
    View in: PubMed
    Score: 0.048
  11. False-Positive Plasma Genotyping Due to Clonal Hematopoiesis. Clin Cancer Res. 2018 09 15; 24(18):4437-4443.
    View in: PubMed
    Score: 0.047
  12. Embryonic transcription factor SOX9 drives breast cancer endocrine resistance. Proc Natl Acad Sci U S A. 2017 05 30; 114(22):E4482-E4491.
    View in: PubMed
    Score: 0.044
  13. Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer. Cancer Discov. 2016 12; 6(12):1334-1341.
    View in: PubMed
    Score: 0.042
  14. In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer. Nat Genet. 2015 Oct; 47(10):1212-9.
    View in: PubMed
    Score: 0.039
  15. Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition. Cancer Res. 2015 Oct 15; 75(20):4372-83.
    View in: PubMed
    Score: 0.039
  16. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015 Jun; 21(6):560-2.
    View in: PubMed
    Score: 0.039
  17. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res. 2014 Mar 15; 20(6):1698-1705.
    View in: PubMed
    Score: 0.035
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.